Markey Study Shows Kentucky Endometrial Cancer Patients Have Higher Rates of DACH1 Mutation

A new study by University of Kentucky Markey Cancer Center researchers shows that DACH1 mutations are prevalent in Kentucky patients with endometrial cancer, suggesting that DACH1 may be a candidate biomarker for future trials with immunotherapy.